Osteoporosis: assessing the risk of fragility fracture
This is an extract from the guidance. The complete guidance is available at guidance.nice.org.uk/cg146
6 Related NICE guidance
-
Patient experience in adult NHS services. NICE clinical guideline 138 (2012).
-
Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. NICE technology appraisal guidance 161 (2011).
-
Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. NICE technology appraisal guidance 160 (2011).
-
The management of hip fracture in adults. NICE clinical guideline 124 (2011).
-
Denosumab for the prevention of osteoporotic fractures in postmenopausal women. NICE technology appraisal guidance 204 (2010).
-
Falls. NICE clinical guideline 21 (2004).